STERIS reports $0.47 per share

DUBLIN, IRELAND, Nov. 02, 2022 (GLOBE NEWSWIRE) — STERIS plc (:STE) (“STERIS” or the “Company”) today announced that the Company will distribute a quarterly interim dividend of $0.47 per stock. The dividend is payable on December 16, 2022 to shareholders of record at the close of business on November 22, 2022.

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER, SAFER WORLD by providing innovative products and services in healthcare, life sciences and dental care. For more information, visit www.steris.com.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

[email protected]

+1.440.392.7245

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This press release may contain statements regarding certain trends, expectations, forecasts, estimates or other forward-looking information affecting or relating to STERIS or its industry, products or businesses that are intended to qualify for the protections afforded “forward-looking statements”. under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as of the date they are made and can be identified by the use of forward-looking words such as “may”, “will”, “expect”, “believe”, “anticipate”, “plans”, “estimates”, “projects”, “targets”, “forecasts”, “outlook”, “impact”, “potential”, “confidence”, “improve”, “optimistic”, “deliver”, “Orders”, “Backlog”, “Comfort”, “Trend” and “Research”, or the negative of these terms or other variations of these terms or comparable terminology. Many important factors could cause actual results to differ materially from those set forth in the forward-looking statements, including, without limitation, disruption of production or supplies, changes in market conditions, events pending or future policies, claims or litigation, competitive factors, advances in technology, actions of regulatory agencies, and changes in laws, government regulations, product labeling or approvals or their application or of their interpretation. Other risk factors are described in STERIS’ other filings, including Section 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 and quarterly reports filed thereafter on 10-Q form. Many of these important factors are beyond the control of STERIS. No assurance can be given as to an outcome or the timing of any outcome with respect to the matters described in STERIS’ securities records or otherwise with respect to any regulatory action, administrative proceeding, governmental investigation, litigation, warning letter , cost reduction, business strategy, profit or revenue trends or future financial results. References to products are summaries only and should not be construed as the specific terms of product authorization or documentation. Except as required by law, STERIS does not undertake to update or revise any forward-looking statements, even if events clearly indicate that the anticipated results, expressed or implied, will not occur. Other potential risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, (a) the impact of the COVID-19 pandemic or similar public health on operations, supply chain, and labor costs, performance, results, prospects or value, (b) the ability of STERIS to achieve the expected benefits with respect to accounting and tax treatment of redomiciliation to Ireland (“Redomiciliation”), (c) operating costs, loss of customers and loss of business disruption (including, without limitation, hardship to maintain relationships with employees, Customers, customers or suppliers) being greater than expected, (d) STERIS’s ability to successfully integrate Cantel Medical’s business into our existing business, including contingent liabilities known or inestimable, or expected integration cost increases or difficulties related to the integration of Cantel Medical (e) STERIS’ ability to meet expectations regarding the accounting and tax treatment of the Tax Cuts and Jobs Act (“TCJA or the possibility that anticipated benefits resulting from the TCJA may be less than estimated, (f) changes in tax laws or interpretations that could increase our consolidated tax liabilities, including changes in tax laws that would have the effect of treat STERIS as a domestic corporation for U.S. federal tax purposes, (g) the possibility of increased pricing or cost pressure resulting in the erosion of profit margins, including as a result of inflation, ( h) the possibility that market demand does not develop for new technologies, products, applications or services, or that commercial initiatives take more time, cost more, or produce lower profits than expected, (i) the possibility that the application of or compliance with any laws, court orders, certifications, regulations or regulatory measures, including, without limitation, any with respect to FDA, EPA or other regulatory authorities, government investigations, the outcome of any FDA, EPA regulatory warning notices or other notices, actions, requests, inspections or pending or threatened bids, the outcome of any pending or imminent litigation brought by private parties, or other requirements or standards may delay, limit or prevent the introduction of new products or services, affect the production, supply and /or the commercialization of existing products or services, incur costs for STERIS which may not be covered by insurance or otherwise affect the performance, results, prospects or value of STERIS , (j) the potential for international unrest, including the Russian-Ukrainian military conflict, economic downturn or currency effects, tax assessments, tariffs and/or other trade barriers, anticipated adjustments or rates, costs or the availability of raw materials, the costs of employee benefit or pension plans, or other regulatory compliance costs, (k) the possibility of reduced demand, or reductions in the rate of demand growth, for STERIS products and services, (l) the possibility of delays in receipt of orders, cancellations of orders, or delays in manufacturing or shipping ordered products, due to supply chain issues or others, or in the provision of services, (m) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental or other issues or risks associated with STERIS’ business, industry or initiatives, including, without limitation, matters described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 and other securities filings, may adversely affect the performance, results, prospects or value of STERIS, (n) the impact on STERIS and its operations, or tax obligations, of Brexit or the exit of other EU member countries, and the ability of the Company to respond to such impacts, (o) the impact on STERIS and its operations of any laws, regulations or orders, including but not limited to any new trade or tax laws, regulations or orders, which may be implemented by the administration or the Congress es American, or any response thereto, (p) the possibility that anticipated financial results or benefits of recent acquisitions, including the acquisition of Cantel Medical and Key Surgical, or STERIS restructuring efforts, or recent divestitures, including anticipated revenues, improved productivity, cost savings, growth synergies and other anticipated benefits, will not or will not materialize. be other than expected, (q) the increase in the level of indebtedness of STERIS incurred in connection with the acquisition of Cantel Medical limiting financial flexibility or increasing future borrowing costs, (r) the actions of the rating or other events that could affect STERIS’ existing debt or its future ability to borrow funds at rates favorable to STERIS or not at all,(s) the potential impact of the acquisition of Cantel Medical on relationships, including with suppliers, customers, employees and regulators, and

Comments are closed.